Platelet transfusion is a common practice in onco-hematologic patients for preventing or
treating hemorrhages. Platelet concentrates can be transfused with therapeutic or …

Despite significant advancements in the production of platelet products, storage, and
transfusion, transfusion refractoriness remains a significant clinical problem, affecting up to …

Cancer patients have varying incidence, depth and duration of thrombocytopenia. The
mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is …

Platelet transfusion refractoriness (PTR) is an intractable issue in hematological patients,
which increases bleeding risks and hospitalization costs to a great extent. We reviewed 108 …

Background Platelet transfusion refractoriness (PTR) remains an intractable issue in clinical
practice, and is common in hematological patients. At present, it is believed that both …

Infantile (fetal and neonatal) megakaryocytes (Mks) have a distinct phenotype consisting of
hyperproliferation, limited morphogenesis, and low platelet production capacity. These …

BACKGROUND Platelet refractoriness due to HLA immunization represents a problem in
transfusion management of thrombocytopenic hematology patients. Refractory patients can …

Aims: This study aimed to estimate the cost of platelet transfusion in patients with chronic
liver disease (CLD)-associated thrombocytopenia undergoing an elective procedure in the …

Objective: Investigate globally, current treatment patterns, benefit-risk assessments,
humanistic, societal and economic burden of platelet transfusion (PT). Methods: Publications …

Platelet transfusion in patients, particularly in onco-haematology, is frequent and can
become chronic in some cases. Post-transfusion alloimmunization is often seen, in practice …